|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
BEFREE |
These findings support a functional mechanism for involvement of CHI3L1 in schizophrenia susceptibility, possibly contributing to a less severe illness.
|
18281018 |
2008 |
|
Schizophrenia
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
Our findings identify CHI3L1 as a potential schizophrenia-susceptibility gene and suggest that the genes involved in the biological response to adverse environmental conditions are likely to play roles in the predisposition to schizophrenia.
|
17160890 |
2007 |
|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Schizophrenia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that higher serum YKL-40 levels are associated with personality trait in patients with schizophrenia.
|
22366530 |
2012 |
|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings identify CHI3L1 as a potential schizophrenia-susceptibility gene and suggest that the genes involved in the biological response to adverse environmental conditions are likely to play roles in the predisposition to schizophrenia.
|
17160890 |
2007 |
|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results suggest that the genetic contribution of CHI3L1 to schizophrenia is variable, even though it is mechanistically involved in the disease process.
|
18767121 |
2009 |
|
Schizophrenia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here we report that CHI3L1 SNPs, shown to be involved in the predisposition of schizophrenia, are not associated with rheumatoid arthritis.
|
20300754 |
2011 |
|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Multivariate Cox regression analyses showed that elevated YKL-40 (hazard ratio (HR) = 5.6, P = 0.001), elevated glucose (HR = 3.6, P = 0.001), and schizophrenia diagnosis (HR = 3.0, P = 0.014) at baseline were associated with subsequent development of type 2 diabetes.
|
30328100 |
2019 |
|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
|
Schizophrenia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Allelic expression imbalance of the schizophrenia susceptibility gene CHI3L1: evidence of cis-acting variation and tissue specific regulation.
|
21642896 |
2011 |
|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Further studies are required to perceive a role of YKL-40 and MCP-1 in the initiation and progression of schizophrenia.
|
30132802 |
2018 |
|
Schizophrenia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
To identify genes associated with schizophrenia, DNA microarray chips were used to compare schizophrenia and control hippocampus tissues, revealing four genes with elevated expression, chondrex (or YKL-40), histamine-releasing factor, HERC2, and heat-shock 70.
|
12872291 |
2003 |
|
Schizophrenia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the genetic variants in the CHI3L1 gene have ethnic heterogeneity and confer a susceptibility to schizophrenia in Asian populations.
|
20051317 |
2010 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In summary, the differential expression of the immunomodulatory molecule YKL-40 may affect the treatment efficacy of PI3K/AKT-based pathway inhibitors in glioblastoma.
|
29729901 |
2018 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this paper, the authors' goal was to evaluate the prognostic value of YKL-40 expression as a prognostic factor for glioblastomas and to compare its validity to the already known MGMT.
|
22655594 |
2012 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High YKL-40 protein expression assessed by immunohistochemistry is found in breast carcinomas associated with short disease-free survival and in glioblastomas with increased resistance to radiotherapy and decreased overall survival.
|
19347297 |
2009 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Taken together our data suggest that the variant allele (-131C-->G) of CHI3L1 promoter has no significant impact on survival and is not a prognostic factor for glioblastoma.
|
19255724 |
2009 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We also found that elevated serum/plasma YKL-40 had significant prognostic effects on OS in various cancer subgroups such as gastrointestinal tumors (HR, 1.37; 95% CI 1.18-1.58), ovarian cancer (HR, 2.27; 95% CI 1.69-3.06), melanoma (HR, 1.77; 95% CI 1.18-2.67), lung cancer (HR, 1.73; 95% CI 1.35-2.23), urologic neoplasms (HR, 1.61; 95% CI 1.08-2.40) and glioblastoma (HR, 1.23; 95% CI 1.07-1.42); in contrast, the prognostic effect of serum/plasma YKL-40 was not statistically significant in breast cancer (HR, 1.07; 95% CI 0.98-1.17).
|
31624472 |
2019 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, this study identifies candidate changes in secreted proteins from NF1 deficient glioma cells that could influence the tumor microenvironment, and suggests a direct link between NF1 loss and increased tumor cell production of CHI3L1 and endoglin, two factors implicated in mesenchymal identity in glioblastoma.
|
29643433 |
2018 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
YKL-40 expression is strongly elevated in serum and biopsy material from glioblastomas patients.
|
15771622 |
2005 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Serum YKL-40 and bone marrow angiogenesis in multiple myeloma.
|
19089918 |
2009 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
YKL-40 expression was also compared with genetically defined subsets of glioblastoma by assessing epidermal growth factor receptor amplification and loss at chromosome 10q, two of the common recurring aberrations in these tumors, using fluorescent in situ hybridization.
|
15867231 |
2005 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to evaluate, in a series of 43 pediatric high-grade gliomas (21 anaplastic astrocytoma WHO grade III and 22 glioblastoma WHO grade IV), the prognostic value of histological grading and expression of p53 and YKL-40.
|
20174854 |
2010 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fitting models with and without YKL-40 highlights a subgroup of patients who have glioblastoma (GBM) diagnosis but appear to have better prognosis than the typical GBM patient.
|
22495652 |
2012 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
YKL-40 up-regulated VEGF expression in glioblastoma cell line U87, and both YKL-40 and VEGF synergistically promote endothelial cell angiogenesis.
|
21385870 |
2011 |